by Sita Bhella, MD, MEd, FRCPC
Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy. The condition is characterized by neurologic symptoms, such as tremors,...
This live session will focus on two core topics in the field — conditioning regimens & immunosuppression management.
This webinar consists of two 30-minute journal club presentations, each including 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the September Journal Club...
by Alex Kadhim
Published in the American Journal of Physical Medicine & Rehabilitation, a brief report explores how cancer patients fare in inpatient rehabilitation after receiving chimeric antigen receptor...
by Alex Kadhim
Researchers at the Children's Hospital of Philadelphia have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the...
by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center have found the addition of tocilizumab, an interleukin-6 receptor blocker, to standard GVHD prophylaxis modestly reduces inflammation-related...